 |
[email protected] |
 |
3275638434 |
 |
 |
| Paper Publishing WeChat |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
177Hf as a Competitor in the Synthesis of 177Lu-DOTAtate
Full-Text PDF
XML 1786 Views
DOI:10.17265/1934-7375/2016.05.007
This study reveals the interference of 177Hf, a decay product of 177Lu, in the synthesis of 177Lu-DOTAtate. In the experiments we followed three 177Lu t1/2. The molar ratio Lu: DOTAtate used was calculated for each decay, in two situations: 1) without considering the influence of 177Hf; 2) considering the influence of 177Hf. The results compare both the calculated molar ratio and the radionuclide incorporation yields (%) in these situations. The yields increase when 177Hf influence is considered. This suggests that 177Hf is an important competitor for DOTAtate binding site. These data are relevant in the synthesis of the radiopharmaceutical 177Lu-DOTAtate with high specific activity.
Hafnium, 177Lu-DOTAtate, molar ratio, radiopharmaceutical.
[1] Krenning, E. P., Valkema, R., Kwekkeboom, D. J., De Herder, W. W., Van Eijck, C. H., De Jong, M., Pawels, S., and Reubi, J. C. 2005. “Molecular Imaging as In Vivo Molecular Phatology for Gastroenteropancreatic Neuroendocrine Tumours: Implications for Follow-up after Therapy.” Journal of Nuclear Medicine 46: 76S-82S.
[2] Reubi, J. C., Macke, H. R., and Krenning, E. P. 2005. “Candidates for Peptide Receptor Radiotherapy Today and in Future.” Journal of Nuclear Medicine 46 (1): 67S-75S.
[3] Schmitt, A., Bernhardt, P., Nilsson, O., Ahlman, H., Kolby, H. R., Maecke, H. R., and Forssel, A. 2004. “Radiation Therapy of Small Cell Lung Cancer with 177Lu-DOTA-Tyr3-octreotate in an Animal Model.” Journal of Nuclear Medicine 45: 1542-8.
[4] Teunissen, J. J. M., Kwekkeboom, D. J., and Krenning, E. P. 2004. “Quality of Life in Patients with Gastroenteropancreatic Tumors Treated with [177Lu-DOTA0, Tyr3]octreotate.” Journal of Clinical Oncology 13: 2724-9.
[5] Forrer, F., Usijarvi, H., Storch, D., Maecke, H. R., and Mueller, B. 2005. “Treatment with 177Lu-DOTATOC of Patients with Relapse of Neurondocrine Tumors after Treatment with 90Y-DOTATOC.” Journal of Nuclear Medicine 46: 1310-6.
[6] Aldo, C., Nicola, d’A., Edmundo, M., Hanh, D. N., Silvio, A., Rolf, E. S., and Karen, E. L. 2009. “Isolation of a Complex Formed by β-Decay of a 177Lu-Labeled Radiotherapeutic Compound and NMR Structural Elucidation of the Ligand and Its Lu and Hf Complexes.” Inorganic Chemistry 48: 3114-24.
[7] Breeman, W. A. P., De Jong, M., Visser, T. J., Erion, J. L., and Krenning, E. P. 2003. “Optimising Conditions for Radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at High Specific Activities.” European Journal of Nuclear Medicine and Molecular Imaging 30: 917-20.
[8] Breeman, W. A. P. 2012. “Practical Aspects of Labeling DTPA-and DOTA-Peptides with 90Y, 111In, 177Lu, and 68Ga for Peptide-Receptor Scintigraphy and Peptice-Receptor Radionuclide Therapy in Preclinical and Clinical Applications.” UNM College of Pharmacy, v. 16, lesson 5.
[9] Caldeira, Filho, J. S. 2009. “Síntese, Análise, Purificação e Biodistribuição em Modelo Animal do Radiofármaco 177Lu3+-DOTATATO Para uso DiagnóStico e Terapêutico em Tumores Neuroendócrinos.” Ph.D. Thesis, Instituto de Pesquisas Energéticas e Nucleares, Universidade de São Paulo, São Paulo. Recuperado em 2014-08-23, de http://www.teses.usp.br/teses/disponiveis/85/85131/tde-02062009-160531/pt-br.php.